TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
In a small single-arm study, 16 breast cancer survivors with cancer-related cognitive impairment who completed eight weeks of oxaloacetate treatment had improved scores on a patient-reported cognitive assessment. The findings are preliminary, and a randomized, placebo-controlled study is expected to begin enrolling before the end of 2026.
A small, uncontrolled study found that 16 breast cancer survivors who completed eight weeks of the supplement oxaloacetate had improved scores on a measure of cancer-related cognitive impairment, according to a report published in JCO Oncology Advances. The early results support plans for a randomized, placebo-controlled trial, but do not establish that the supplement caused the improvement or that it works better than a placebo.
The study enrolled 18 patients, all of whom were one to five years beyond cancer treatment and had a questionnaire score indicating moderately severe cognitive impairment. Participants took 500 milligrams of oxaloacetate twice daily for eight weeks. Sixteen completed the study and were included in the reported evaluable results.
On the FACT-Cog PCI, a patient-reported measure of perceived cognitive impairment, the average score among those assessed rose from 29.1 at baseline to 55.5 after eight weeks. The study authors said this represented movement from an impaired range into the normal range. Scores had improved by week four and generally continued to rise during the remaining four weeks. Neuropsychological testing also showed improvement in executive function and processing speed.
The investigators reported improvements in fatigue and physical functioning, with a trend toward improvement in insomnia. Gastrointestinal complaints, including indigestion, bloating, constipation and diarrhea, were among the commonly reported side effects. The source report described the treatment as generally well tolerated, while noting that the study was small and had no control group.
Cancer-related cognitive impairment can affect memory, concentration and other thinking skills after cancer or its treatment. Patients and clinicians have limited pharmacological options for the condition, making a possible treatment approach relevant even at an early research stage. The study also reported changes in fatigue and physical functioning, symptoms that can compound difficulties in daily life.
But the results should be read as a signal for further study, not evidence that oxaloacetate is an established treatment. Without a comparison group, researchers cannot separate a treatment effect from factors such as expectations, natural changes over time or other influences. A controlled trial is needed to test whether the improvement is attributable to the supplement and whether it is clinically useful.
oxaloacetate supplement capsules 500 mg
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Why Researchers Studied Oxaloacetate
The precise causes and mechanisms of cancer-related cognitive impairment remain unclear. The condition is often called “chemo brain” or “brain fog,” though cognitive problems are not limited to people who received chemotherapy. The source report notes that some chemotherapy drugs can cross the blood-brain barrier and have recognized neurotoxic effects; earlier research has suggested a relationship between chemotherapy intensity and cognitive dysfunction.
Oxaloacetate is a naturally occurring human metabolite involved in cellular energy production and in the regulation of glutamate, a neurotransmitter studied for its role in cognition. Prior research, including a small randomized study involving people with long COVID symptoms, provided a rationale for testing it in cancer survivors. That background does not establish that it improves cognition in this population; the breast cancer study was an early investigation.
The research team initially set a target of a four-point improvement on the FACT-Cog PCI among the first nine participants. The report says the preliminary analysis showed a 27-point improvement, after which the investigators changed the study design to complete the work with a smaller total sample and move more quickly toward a randomized trial. The report does not provide enough detail to assess how that design change affected the analysis.
“These early findings give us a strong reason to continue studying oxaloacetate as a potential approach for managing cognitive problems after breast cancer treatment.”
— Patricia Ganz, MD, of UCLA Health, in a press release
What the Small Study Cannot Show
The study included only 18 participants, had no placebo or control group, and reported outcomes for 16 people who completed treatment. Its findings cannot show whether oxaloacetate itself caused the score changes, how it compares with placebo or other care, or whether the improvements persist after treatment ends. The report also does not specify the reasons the two participants did not complete the study.
The available information does not establish whether the findings apply to people with other cancers, people currently receiving treatment or patients with different levels of cognitive impairment. Longer-term safety and the frequency of side effects also remain to be clarified. A larger controlled trial is needed before the supplement’s effectiveness and risks can be assessed with greater confidence.
A Placebo-Controlled Trial Is Planned
The source report said a phase II randomized, placebo-controlled study was expected to begin enrollment before the end of 2026. That trial should provide a comparison group, a key step in testing whether changes in cognitive scores are linked to oxaloacetate rather than other factors. The report did not provide a planned enrollment total, study sites, or a projected completion date.
Until results from controlled research are available, the study offers preliminary evidence rather than a basis for conclusions about treatment. Further reporting can assess whether enrollment begins as expected and what the larger trial finds about cognitive outcomes, side effects and the duration of any benefit.
Key Questions
What did the oxaloacetate study find?
Among 16 participants who completed the study, average scores on a patient-reported cognitive impairment measure rose from 29.1 before treatment to 55.5 after eight weeks. Researchers also reported improvement in fatigue and physical functioning. Because there was no control group, the study cannot establish that oxaloacetate caused these changes.
Who took part in the study?
The study enrolled 18 breast cancer survivors who were one to five years beyond cancer treatment and met a questionnaire threshold for moderately severe cognitive impairment. Sixteen completed the eight-week study.
No. The findings are preliminary and come from a small, uncontrolled study. A randomized trial comparing oxaloacetate with placebo is needed to test whether the supplement improves symptoms beyond what might occur for other reasons.
What side effects were reported?
The report listed gastrointestinal symptoms including indigestion, bloating, constipation and diarrhea among the commonly reported adverse effects. It did not provide enough detail here to determine how often each occurred or to assess longer-term safety.
When will the next study begin?
A phase II placebo-controlled study was expected to begin enrollment before the end of 2026, according to the report. Its enrollment size and completion timeline were not specified.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
